State Street Corp Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

State Street Corp purchased a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 86,559 shares of the company’s stock, valued at approximately $1,337,000.

Several other hedge funds also recently made changes to their positions in the stock. RA Capital Management L.P. purchased a new stake in Artiva Biotherapeutics during the 3rd quarter worth about $152,234,000. Samsara BioCapital LLC bought a new stake in shares of Artiva Biotherapeutics during the third quarter valued at about $4,506,000. RTW Investments LP purchased a new stake in shares of Artiva Biotherapeutics in the third quarter worth about $2,300,000. Acuta Capital Partners LLC bought a new position in shares of Artiva Biotherapeutics in the third quarter valued at approximately $680,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Artiva Biotherapeutics during the third quarter valued at approximately $623,000.

Artiva Biotherapeutics Trading Down 1.1 %

Shares of ARTV opened at $9.97 on Friday. Artiva Biotherapeutics, Inc. has a 1-year low of $9.68 and a 1-year high of $17.31. The company has a 50 day moving average of $11.36.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24). On average, analysts anticipate that Artiva Biotherapeutics, Inc. will post -4.68 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on ARTV shares. HC Wainwright began coverage on shares of Artiva Biotherapeutics in a research note on Monday. They issued a “buy” rating and a $20.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $21.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.